Shots:

• The P-III (SOLSTICE) trial evaluates Livtencity (400 mg, bid) vs conventional antiviral therapy in a ratio (2:1) in 352 HCT & SOT recipients with CMV infection refractory with/out resistance to one or a combination of conventional antiviral therapies
• The trial meet its 1EPs & 2EPs i.e., patients achieved 55.7% (131/235) vs 23.9% (28/117) confirmed CMV DNA level @8wks., symptom control @8wks. & maintained @16wks., higher proportion of patients meet the EPs (18.7%, 44/235) vs (10.3%, 12/117); treatment discontinuation due to AEs (13%, 31/234 vs 32%, 37/116)
• Livtencity is an orally bioavailable anti-CMV compound &  1st antiviral agent that target pUL97 protein kinase & natural substrates

 Ref: Takeda | Image: Takeda